{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T15:05:04Z","timestamp":1794841504418,"version":"4.9.1"},"reference-count":56,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T00:00:00Z","timestamp":1765324800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011022","name":"Vertex Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2595884","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:54:58Z","timestamp":1765374898000},"page":"2135-2149","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Budget impact of suzetrigine for the treatment of moderate-to-severe acute pain in Medicaid-insured adults"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0726-7175","authenticated-orcid":false,"given":"Kenna","family":"Garrison","sequence":"first","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5128-0255","authenticated-orcid":false,"given":"Alexandra G.","family":"Ellis","sequence":"additional","affiliation":[{"name":"Stratevi","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy G.","family":"Curtice","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2579-1083","authenticated-orcid":false,"given":"Melissa M.","family":"Rosen","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4360-6278","authenticated-orcid":false,"given":"Matthew","family":"Sussman","sequence":"additional","affiliation":[{"name":"Stratevi","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Lee","sequence":"additional","affiliation":[{"name":"Stratevi","place":["Santa Monica, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Lopez","sequence":"additional","affiliation":[{"name":"Vertex Pharmaceuticals Incorporated","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1053\/ajem.2002.32643"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000001384"},{"key":"e_1_3_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnx019"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12760"},{"key":"e_1_3_7_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.657"},{"key":"e_1_3_7_7_1","volume-title":"Poster presented at: 2023 ASRA Pain Medicine 22nd Annual Medical Meeting","author":"Lopez A","unstructured":"Lopez A, Jones J, Menzie A, et al. An evaluation of the prevalence of acute and chronic pain medication use in the United States: a real world database analysis. Poster presented at: 2023 ASRA Pain Medicine 22nd Annual Medical Meeting; New Orleans, LA, USA."},{"key":"e_1_3_7_8_1","unstructured":"Acetaminophen injection [prescribing information]. B. Braun Medical Inc; 2021."},{"issue":"1","key":"e_1_3_7_9_1","first-page":"63","article-title":"Pharmacologic therapy for acute pain","volume":"104","author":"Amaechi O","year":"2021","unstructured":"Amaechi O, Huffman MM, Featherstone K. Pharmacologic therapy for acute pain. Am Fam Physician. 2021;104(1):63\u201372.","journal-title":"Am Fam Physician"},{"key":"e_1_3_7_10_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr7103a1"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000003777"},{"key":"e_1_3_7_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.04.1907"},{"key":"e_1_3_7_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000005372"},{"key":"e_1_3_7_14_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6610a1"},{"key":"e_1_3_7_15_1","volume-title":"Economic impact of non-medical opioid use in the United States: annual estimates and projections for 2015 through 2019","author":"Davenport S","year":"2019","unstructured":"Davenport S, Weaver A, Caverly M. Economic impact of non-medical opioid use in the United States: annual estimates and projections for 2015 through 2019. Society of Actuaries; 2019. Available from: https:\/\/www.soa.org\/globalassets\/assets\/files\/resources\/research-report\/2019\/econ-impact-non-medical-opioid-use.pdf"},{"key":"e_1_3_7_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.5968"},{"key":"e_1_3_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.108350"},{"key":"e_1_3_7_18_1","volume-title":"PAINWeek","author":"Schoenfeld AJ","year":"2023","unstructured":"Schoenfeld AJ, Badgley D, Badora K, et al. The societal impact of prescription opioid use and opioid use disorder in the United States: a current perspective 2016\u20132023. Poster presented at: PAINWeek. Las Vegas, Nevada, USA; 2023."},{"key":"e_1_3_7_19_1","unstructured":"National Institute on Drug Abuse. Drug overdose deaths: facts and figures 2024; 2025."},{"key":"e_1_3_7_20_1","unstructured":"US Centers for Disease Control and Prevention. Medications for opioid use disorder (MOUD) study 2024; 2025. Available from: https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/moud-study.html."},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2602385"},{"key":"e_1_3_7_22_1","volume-title":"Poster presented at: PainConnect 2025, AAPM Annual Meeting","author":"Ballreich JM","unstructured":"Ballreich JM, Jeyakumar S, Garrison K, et al. Impact of opioids prescribed for acute pain management on the societal burden of the US opioid epidemic and the potential impact of an effective non-opioid treatment for acute pain. Poster presented at: PainConnect 2025, AAPM Annual Meeting; Austin, TX, USA."},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2021.88617"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-2263-6"},{"key":"e_1_3_7_25_1","unstructured":"Drug therapeutics & regulation in the US. US Food and Drug Administration; 2023. Available from: https:\/\/www.fda.gov\/about-fda\/fda-history-exhibits\/drug-therapeutics-regulation-us."},{"key":"e_1_3_7_26_1","unstructured":"US Food and Drug Administration. Timeline of selected FDA activities and significant events addressing substance use and overdose prevention; 2025. Available from: https:\/\/www.fda.gov\/drugs\/food-and-drug-administration-overdose-prevention-framework\/timeline-selected-fda-activities-and-significant-events-addressing-substance-use-and-overdose."},{"key":"e_1_3_7_27_1","unstructured":"JOURNAVX. [prescribing information]. Boston MA: Vertex Pharmaceuticals Incorporated; 2025."},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/ALN.0000000000005460"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S509144"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.08.2291"},{"key":"e_1_3_7_31_1","unstructured":"Centers for Medicare & Medicaid Services. October 2024 Medicaid & CHIP eligibility operations and enrollment snapshot; 2024."},{"key":"e_1_3_7_32_1","unstructured":"Vertex Pharmaceuticals Incorporated. Data on file; 2025."},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-022-01476-y"},{"key":"e_1_3_7_34_1","unstructured":"US Bureau of Labor Statistics. Consumer price index for all urban consumers: medical care in US city average; 2025."},{"key":"e_1_3_7_35_1","unstructured":"ROXYBOND (oxycodone hydrochloride). [package insert]. Valley Cottage NY: Inspirion Delivery Sciences LLC; 2017."},{"key":"e_1_3_7_36_1","unstructured":"NORCO (hydrocodone bitartrate and acetaminophen). [package insert]. Madison NJ: Allergan USA; 2019."},{"key":"e_1_3_7_37_1","unstructured":"ULTRAM (tramadol hydrochloride). [package insert]. Titusville NJ: Janssen Pharmaceuticals; 2023."},{"key":"e_1_3_7_38_1","unstructured":"NEURONTIN (gabapentin). [package insert]. Morgantown WV: Viatris Specialty LLC; 2024."},{"key":"e_1_3_7_39_1","unstructured":"Merative. Micromedex RED BOOK; 2025."},{"key":"e_1_3_7_40_1","unstructured":"Centers for Medicare & Medicaid Services. Unit rebate amount information 2025; 2025. Available from: https:\/\/www.medicaid.gov\/medicaid\/prescription-drugs\/medicaid-drug-rebate-program\/unit-rebate-amount-calculation."},{"key":"e_1_3_7_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2010.02.007"},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-016-0057-y"},{"key":"e_1_3_7_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2024.100709"},{"key":"e_1_3_7_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12768"},{"key":"e_1_3_7_45_1","unstructured":"Rind DM McQueen B Nikitin D et al. Suzetrigine for acute pain; final evidence report. Institute for Clinical and Economic Review; 2025. https:\/\/icer.org\/assessment\/acute-pain-2025\/."},{"key":"e_1_3_7_46_1","unstructured":"IPD Analytics. Journavx for moderate to severe acute pain; 2025."},{"key":"e_1_3_7_47_1","unstructured":"Saunders H Euhus R Burns A et al. SUD treatment in Medicaid: variation by service type demographics states and spending: Kaiser Family Foundation; 2024."},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.45691"},{"key":"e_1_3_7_49_1","unstructured":"Medicaid and CHIP Payment and Access Commission. Medicaid and the opioid epidemic; 2017."},{"key":"e_1_3_7_50_1","unstructured":"Temple University Center for Public Health Law Research. Opioid analgesics prescribing limits; 2019. Available from: https:\/\/pdaps.org\/datasets\/opioid-analgesics-prescribing-limits."},{"key":"e_1_3_7_51_1","unstructured":"Federation of State Medical Review Boards. Prescription drug monitoring programs: state-by-state overview; 2024."},{"key":"e_1_3_7_52_1","unstructured":"State Bill Tracker. Families addiction & mental health network; 2025. Available from: https:\/\/www.fam-network.org\/bills\/."},{"key":"e_1_3_7_53_1","unstructured":"State Legislation to Support Pain Parity. Families addiction & mental health network; 2025. Available from: https:\/\/www.families-network.org\/issues\/state\/."},{"key":"e_1_3_7_54_1","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S144066"},{"key":"e_1_3_7_55_1","unstructured":"Medicaid Medicare.gov: Centers for Medicare & Medicaid Services. 2025. Available from: https:\/\/www.medicare.gov\/basics\/costs\/help\/medicaid."},{"key":"e_1_3_7_56_1","unstructured":"Centers for Medicare & Medicaid Services. January 2025 Medicaid & CHIP eligibility operations and enrollment snapshot; 2025."},{"key":"e_1_3_7_57_1","unstructured":"Medicaid and CHIP Payment and Access Commission. An updated look at rates of churn and continuous coverage in Medicaid and CHIP; 2021."}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2595884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:46:33Z","timestamp":1766400393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2595884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2595884"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2595884","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-09-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}